Fibrinolytic Disorders
- 138 Downloads
Synonyms
Fibrinolytic defects; Abnormalities of the fibrinolytic system; Disfibrinolysis
Definition and Characteristics
Congenital or acquired abnormalities of the fibrinolytic system leading to hypo- or hyperfibrinolysis due to impaired activity of plasmin, its inhibitors, or plasminogen (PLG) activators.
Prevalence
Primary genetic disorders of fibrinolysis are uncommon, acquired fibrinolytic disorders are frequent, and secondary to other primary disorders or therapeutic interventions.
Genes
PLG coding for the plasminogen, localized or chromosome 6q26-6q27; SERPINF2 – alpha-2-plasmin inhibitor, 17p13; SERPINE1 – plasminogen activator inhibitor type 1, 7q21.3; PLAT – tissue plasminogen activator, 8p12-8p11; PLAU – urokinase-type plasminogen activator, 10q24; CPB2 – carboxypeptidase B2 (plasma) (thrombin-activatable fibrinolysis inhibitor), 13q14.1; UPAR – plasminogen activator receptor, urokinase-type (urokinase receptor), 19q13.2.
Molecular and Systemic Pathophysiology
References
- 1.Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Br J Haematol 129:307–321PubMedGoogle Scholar
- 2.Schuster V, Hugle B, Tefs K (2007) Plasminogen defiency. J Thromb Haemost 5:2315–2322Google Scholar
- 3.Syrovets T, Simmet T (2004) Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 61:873–885PubMedGoogle Scholar
- 4.Longstaff C, Thelwell C (2005) Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Lett 579:3303–3309PubMedGoogle Scholar
- 5.Cale JM, Lawrence DA (2007) Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets 8:971–981PubMedGoogle Scholar